EGFR and colorectal carcinoma: Based on the tumoroid platform, combination treatment consisting of EGFR pathway blockade and AURKA inhibition was found to be probably effective for chemoresistant CRC liver metastases with acquired KRAS mutation and increased expression of AURKA and c-MYC as a second-line treatment candidate [168].